Cardiovascular effects of antipsychotics.

Abstract:

:There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipidemia, the metabolic syndrome and Type 2 diabetes. One factor that increases cardiovascular risk is the medications used to treat the core features of schizophrenia. Adverse cardiovascular effects of antipsychotic treatment have been recognized for many decades, especially tachycardia, orthostatic hypotension and rare instances of sudden death; but, since 2000, there has been a significant shift in the focus of risk perception. The older antipsychotic literature is replete with papers primarily concerned with the physiological consequences of muscarinic cholinergic antagonism, alpha(1)-adrenergic antagonism or receptors associated with cardiac conduction, but the current literature recognizes that, for most antipsychotic-exposed patients, the more significant cardiovascular burden of treatment is mediated by metabolic adverse effects such as weight gain, dyslipidemia and diabetes mellitus. The purpose of this review is to examine the cardiovascular risks of treatment with antipsychotic medications, elucidating relevant mechanisms and differences between various agents, especially for metabolic adverse effects seen with atypical antipsychotics.

journal_name

Expert Rev Neurother

authors

Michelsen JW,Meyer JM

doi

10.1586/14737175.7.7.829

subject

Has Abstract

pub_date

2007-07-01 00:00:00

pages

829-39

issue

7

eissn

1473-7175

issn

1744-8360

journal_volume

7

pub_type

杂志文章,评审
  • No evidence of disease activity in multiple sclerosis patients.

    abstract:INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1202763

    authors: Matta AP,Nascimento OJ,Ferreira AC,Magalhães TN,Benevides TP,Kirmse A,Dib JG,Cal H,Orsini M,Araujo LM

    更新日期:2016-11-01 00:00:00

  • Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.

    abstract::Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication. Rufinamide is a new antiepileptic drug approved as adjunctive therapy ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.51

    authors: Ferrie CD

    更新日期:2010-06-01 00:00:00

  • Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon.

    abstract::In different study populations, several studies have shown that modest C-reactive protein elevation, in the range of apparently healthy individuals, is a strong predictor of future vascular events. Willcox and colleagues summarize the epidemiological and clinical observations that have led to the enthusiastic suggesti...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章,评审

    doi:10.1586/14737175.4.4.613

    authors: Di Napoli M,Papa F

    更新日期:2004-07-01 00:00:00

  • Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.

    abstract::Glucocorticoids exert a variety of immunomodulatory activities. Since changes in glucocorticoid homeostasis impact on susceptibility to autoimmune diseases, and synthetic glucocorticoids are widely used in the treatment of multiple sclerosis, a detailed understanding of their mechanism of action is desirable. Experime...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.11.1657

    authors: Reichardt HM,Gold R,Lühder F

    更新日期:2006-11-01 00:00:00

  • An update on the recognition and treatment of non-convulsive status epilepticus in the intensive care unit.

    abstract:INTRODUCTION:Non-convulsive status epilepticus (NCSE) is a complex and diverse condition which is often an under-recognised entity in the intensive care unit. When NCSE is identified the optimal treatment strategy is not always clear. Areas covered: This review is based on a literature review of the key literature in t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1369880

    authors: Kinney MO,Kaplan PW

    更新日期:2017-10-01 00:00:00

  • Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

    abstract:INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1326818

    authors: Khan A,Corbett A,Ballard C

    更新日期:2017-07-01 00:00:00

  • Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

    abstract::Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1028370

    authors: Rizzo R,Martino D

    更新日期:2015-04-01 00:00:00

  • Effect of second-generation antipsychotics on cognition: current issues and future challenges.

    abstract::Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.143

    authors: Hill SK,Bishop JR,Palumbo D,Sweeney JA

    更新日期:2010-01-01 00:00:00

  • Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice.

    abstract::Introduction: Despite increased interest in the pharmacotherapy of bipolar disorder during pregnancy and the postpartum period, management of the disorder during these critical periods in a woman's life remains challenging.Areas covered: The authors review the effect of pregnancy and the postpartum period on the cours...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1743684

    authors: Sharma V,Sharma P,Sharma S

    更新日期:2020-04-01 00:00:00

  • Dual tasking in Parkinson's disease: should we train hazardous behavior?

    abstract::Dual-task (DT) circumstances aggravate gait disorders in Parkinson's disease (PD) and are associated with an increased risk of falling and reduced functional mobility. Clinical rehabilitation guidelines for PD consider DT interventions as potentially hazardous and recommend avoiding them in daily life. The current art...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1077116

    authors: Strouwen C,Molenaar EA,Münks L,Keus SH,Bloem BR,Rochester L,Nieuwboer A

    更新日期:2015-01-01 00:00:00

  • Acetyl-l-carnitine as a possible therapy for Alzheimer's disease.

    abstract::Alterations have been demonstrated in membrane phospholipid metabolism in Alzheimer's disease. Alterations in membrane phospholipid metabolite levels have been observed by 31P magnetic resonance spectroscopy 4 years before onset of cognitive changes. Implications of phospholipid membrane changes in Alzheimer's disease...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.5.647

    authors: Pettegrew JW,McClure RJ

    更新日期:2002-09-01 00:00:00

  • Chemotherapy for malignant glioma.

    abstract::Malignant gliomas comprise a small percentage of all cancers, but continue to cause disproportionate levels of morbidity and mortality. Despite decades of intensive effort from many disciplines--surgery, radiation oncology and medicine--they remain refractory to cure and, in most cases, even to prolonged treatment res...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.S41

    authors: Nicholas MK,Lukas R,Bangalore S

    更新日期:2005-11-01 00:00:00

  • Poor insight into schizophrenia: contributing factors, consequences and emerging treatment approaches.

    abstract::Poor insight or unawareness of illness has been commonly observed in schizophrenia and has been long recognized as a potent barrier to treatment adherence and a risk factor for a range of poorer outcomes. Paradoxically, the achievement of insight often poses a different set of problems including depression and low sel...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.811150

    authors: Lysaker PH,Vohs J,Hillis JD,Kukla M,Popolo R,Salvatore G,Dimaggio G

    更新日期:2013-07-01 00:00:00

  • Cognitive dysfunction in multiple sclerosis: current approaches to clinical management.

    abstract::In the last two decades clinicians have become increasingly aware of the frequency, importance and functional impact of cognitive dysfunction in multiple sclerosis. There is, however, a dearth of research in this area. In order to further progress in the field of neuropsychological diagnosis it is essential to validat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.5.731

    authors: Amato MP,Zipoli V

    更新日期:2002-09-01 00:00:00

  • Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.

    abstract::Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1621750

    authors: Kuo YC,Rajesh R

    更新日期:2019-07-01 00:00:00

  • Genetics of schizophrenia: implications for treatment.

    abstract::Schizophrenia is a common, debilitating illness for which treatment is empirical and unsatisfactory. Intense efforts to identify etiological factors have been launched in order to facilitate rational therapy. Such efforts have included gene-mapping studies since a significant heritability has been proved. In common wi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.4.725

    authors: Northup A,Nimgaonkar VL

    更新日期:2004-07-01 00:00:00

  • Fingolimod for the treatment of relapsing multiple sclerosis.

    abstract::Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of l...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.193

    authors: Jeffery DR,Markowitz CE,Reder AT,Weinstock-Guttman B,Tobias K

    更新日期:2011-02-01 00:00:00

  • Combination treatments in Alzheimer's disease: risks and benefits.

    abstract::Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.43

    authors: Sobow T

    更新日期:2010-05-01 00:00:00

  • What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?

    abstract::The kynurenine pathway has received increasing attention as its connection to inflammation, the immune system and neurological conditions has become more apparent. It is the primary route for tryptophan catabolism in the liver and the starting point for the synthesis of nicotinamide adenine dinucleotide in mammals. Dy...

    journal_title:Expert review of neurotherapeutics

    pub_type: 社论

    doi:10.1586/14737175.2015.1049999

    authors: Davis I,Liu A

    更新日期:2015-01-01 00:00:00

  • The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials.

    abstract::The prevalence rate of chronic pain is 15% to 25% in adults while the therapeutic arsenal is still insufficient, especially in relieving neuropathic pain. Peripheral pain transmission is conducted by the small Aδ and C sensory nerve fibres. They express elements from the renin-angiotensin-aldosterone system (RAAS), a ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2016.1150179

    authors: Bessaguet F,Magy L,Desmoulière A,Demiot C

    更新日期:2016-01-01 00:00:00

  • Stroke in systemic lupus erythematosus.

    abstract::With improved control of the immunological phenomena of systemic lupus erythematosus, the epidemiology of this disease is changing. While both cardiac and neurological manifestations of systemic lupus erythematosus have been consistently described, there is increasing awareness of the need for general cardiovascular p...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.3.385

    authors: Wierzbicki AS

    更新日期:2002-05-01 00:00:00

  • Evaluation of malnutrition in patients with nervous system disease.

    abstract::Nutritional deficiencies are independent risk factors for adverse outcomes in patients with nervous system disease. Patients with nervous system disease can often become malnourished due to swallowing difficulties or unconsciousness. This malnourishment increases hospitalization duration; average total hospital cost; ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.957184

    authors: Li F,Liu YW,Wang XF,Liu GW

    更新日期:2014-10-01 00:00:00

  • Epilepsy in the elderly.

    abstract::Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.170

    authors: Johnston A,Smith PE

    更新日期:2010-12-01 00:00:00

  • Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers.

    abstract::Alzheimer's disease is an age-related dementia and its incidence is rising in developed countries as the population ages. Amyloid plaques and tau-rich neurofibrillary tangles are pathologic hallmarks of the disease. Treatment is symptomatic, consisting of compounds that block enzymatic acetylcholine degradation (acety...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.1.97

    authors: Silverberg GD,Mayo M,Saul T,Carvalho J,McGuire D

    更新日期:2004-01-01 00:00:00

  • Repetitive transcranial magnetic stimulation as treatment for anxiety disorders.

    abstract::Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive and generally well-tolerated method of focally stimulating brain regions. It has been shown to be efficacious in the treatment for depression, but only to a limited degree. It has also been investigated for the treatment of some anxiety disorders, pa...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.8.10.1449

    authors: Pigot M,Loo C,Sachdev P

    更新日期:2008-10-01 00:00:00

  • Pseudotumor cerebri presenting as headache.

    abstract::Pseudotumor cerebri (PTC) is characterized by intracranial hypertension without ventriculomegaly, in the absence of a mass lesion or meningeal process. When there is no secondary cause, it is termed 'idiopathic intracranial hypertension'. Headache is the most common symptom of PTC, present in over 90% of patients. The...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.3.397

    authors: Friedman DI

    更新日期:2008-03-01 00:00:00

  • Use of neural stem cells as therapeutic vehicles for the treatment of malignant glioma.

    abstract::The prognosis for patients with malignant glioma, the most common primary intracranial neoplasm, remains dismal despite significant progress in neuro-oncological therapies and technology. This stems from the inability of current treatment strategies to address the highly invasive nature of this disease. Malignant glia...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.6.883

    authors: Ehtesham M,Kabos P,Black KL,Yu JS

    更新日期:2003-11-01 00:00:00

  • Stroke rehabilitation using noninvasive cortical stimulation: aphasia.

    abstract::Poststroke aphasia results from the lesion of cortical areas involved in the motor production of speech (Broca's aphasia) or in the semantic aspects of language comprehension (Wernicke's aphasia). Such lesions produce an important reorganization of speech/language-specific brain networks due to an imbalance between co...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.76

    authors: Mylius V,Zouari HG,Ayache SS,Farhat WH,Lefaucheur JP

    更新日期:2012-08-01 00:00:00

  • Antiepileptic drug therapy and recommendations for withdrawal in patients with seizures and epilepsy due to neurocysticercosis.

    abstract:INTRODUCTION:Neurocysticercosis (NCC) is a leading causes of secondary epilepsy worldwide. There is increasing evidence on the epileptogenic role of NCC, and the presence of edema, calcified scars, gliosis and hippocampal sclerosis support this phenomenon. AREAS COVERED:We summarized principles of antiepileptic drug (...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194757

    authors: Bustos JA,García HH,Del Brutto OH

    更新日期:2016-09-01 00:00:00

  • Response of gait deficits to neuromuscular electrical stimulation for stroke survivors.

    abstract::Persistent gait deficits after stroke can cause falls, elevated energy cost and poor endurance. Coordination impairment is an underlying cause of gait deficits. Few efficacious interventions have been described that have targeted and measured restoration of coordinated gait components. Neuromuscular electrical stimula...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.10.1511

    authors: Daly JJ

    更新日期:2006-10-01 00:00:00